Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Relief Therapeutics Holding AG (RLF) CHF0.01

Sell:0.13 CHF Buy:0.14 CHF Change: 0.0025 CHF (1.90%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.13 CHF
Buy:0.14 CHF
Change: 0.0025 CHF (1.90%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.13 CHF
Buy:0.14 CHF
Change: 0.0025 CHF (1.90%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.

Contact details

Batiment F2/F3, Avenue de Secheron 15
+41 (44) 7235959

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
579.88 million CHF
Shares in issue:
4.41 billion
SIX Swiss Exchange
Swiss Franc

Key personnel

  • Raghuram Selvaraju
    Chairman of the Board
  • Jack Weinstein
    Chief Financial Officer, Treasurer
  • Taneli Jouhikainen
    Chief Operating Officer
  • Gilles Della Corte
    Chief Medical Officer
  • Christiaan Stijnen
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.